NCT06066333View on ClinicalTrials.gov

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

September 27, 2026

Study Completion Date

September 27, 2026

Conditions
Adrenocortical CarcinomaACCMetastatic Adrenocortical Carcinoma
Interventions
RADIATION

Ablative Radiotherapy

All participants will first undergo ablative RT

DRUG

Pembrolizumab

After completion of ablative RT, all subjects may begin pembrolizumab treatment

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack, Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER